Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov;118(5):1090-1099.
doi: 10.1002/cpt.70070. Epub 2025 Sep 19.

Operationalizing Decentralized Clinical Trials: Technology Insights from the Trials@Home RADIAL Proof-of-Concept Trial

Affiliations

Operationalizing Decentralized Clinical Trials: Technology Insights from the Trials@Home RADIAL Proof-of-Concept Trial

Sten Hanke et al. Clin Pharmacol Ther. 2025 Nov.

Abstract

While decentralized clinical trials (DCTs) hold great promise for improving trial accessibility and efficiency, the effective deployment of DCT elements requires robust technological infrastructure and careful system integration. Although several innovative technologies are now available for implementing DCT elements, most existing setups integrate single-vendor solutions, which restrict the potential for tailored trial designs as well as seamless interoperability between different platforms and solutions. This paper presents operational learnings from the Trials@Home RADIAL proof-of-concept trial. RADIAL implemented a modular, multi-vendor technology package. RADIAL adopted a deliberate strategy to avoid a monolithic "one-vendor-for-all" solution, instead selecting technologies and integrating them only where it added clear value. Core systems-such as eConsent and Bluetooth glucometer-were fully integrated into the central platform, while other components were deliberately managed outside the core system. The aim was to implement and validate a multi-vendor technology setup and generate learnings that would help DCT trialist in designing DCTs, especially in terms of technology selection and integration. Key challenges arose from Bring Your Own Device (BYOD) variability, immature device technologies, and infrastructure limitations at clinical sites-particularly affecting components like telemedicine. The results emphasize the significance of investing in participant support infrastructure, as well as early cross-functional support, while automated, multichannel notifications seem to guide participant engagement. Finally, embedding compliance by planning early streamlines documentation through a clear governance model seemed to enhance agility and reduce burden.

PubMed Disclaimer

Conflict of interest statement

RD is working for eClinicalHealth and staff is eligible for an options plan. All other authors declared no competing interests for this work.

Figures

Figure 1
Figure 1
Overview of RADIAL’s hub‐and‐spoke technology architecture. EDC, Electronic Data Capture; ePRO, electronic Patient‐Reported Outcome; eConsent, electronic Consent; eDiary, electronic Diary; RTSM, Randomization and Trial Supply Management.
Figure 2
Figure 2
Integration of the insulin treatment adherence system.

References

    1. Santa‐Ana‐Tellez, Y. et al. Decentralised, patient‐centric, site‐less, virtual, and digital clinical trials? From confusion to consensus. Drug Discov. Today 28, 103520 (2023). - PubMed
    1. Betcheva, L. , Kim, J.Y. , Erhun, F. , Oraiopoulos, N. & Getz, K. Applying systems thinking to inform decentralized clinical trial planning and deployment. Ther. Innov. Regul. Sci. 57, 1081–1098 (2023). - PMC - PubMed
    1. Narasimhan, S. Decentralized clinical trials – systematic review of methods, awareness, and inclusiveness in clinical research. Texila Int. J. Acad. Res. 10, 113–124 (2023).
    1. swissmedic . Position Paper on decentralised clinical trials (DCTs) with medicinal products in Switzerland (2022).
    1. Sinha, S.D. , Chary Sriramadasu, S. , Raphael, R. & Roy, S. Decentralisation in clinical trials and patient centricity: benefits and challenges. Pharm. Med. 38, 109–120 (2024). - PubMed